Important News from AbbVie

AbbVie (ABBV) submitted a biological license application (BLA) to the United States’ FDA for its sensational product trenibotulinumtoxinE (TrenibotE), which reduces frown lines between the eyebrows, known as glabellar lines.

The Product

TrenibotE is a botulinum toxin of serotype E with short effects of a long duration for the users. The product is safer than the existing . . .